139 related articles for article (PubMed ID: 35834987)
21. Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Royston L; Masouridi-Levrat S; Gotta V; Royston E; Pressacco-Brossier C; Abi Aad Y; Tonoli D; Karmime A; Jayo M; Van Delden C; Lescuyer P; Pfister M; Chalandon Y; Neofytos D
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0065722. PubMed ID: 35876579
[TBL] [Abstract][Full Text] [Related]
22. TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).
Kuijvenhoven MA; Wilhelm AJ; Meijer E; Janssen JJWM; Swart EL
Eur J Haematol; 2021 Sep; 107(3):364-369. PubMed ID: 34114691
[TBL] [Abstract][Full Text] [Related]
23. Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China.
Liu L; Zhou X; Wu T; Jiang H; Yang S; Zhang Y
Int J Antimicrob Agents; 2017 Apr; 49(4):483-487. PubMed ID: 28159657
[TBL] [Abstract][Full Text] [Related]
24. [Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data].
Xu G; Chen E; Mao E; Che Z; He J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):640-645. PubMed ID: 30045790
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after sorafenib intake.
Ba HL; Mbatchi L; Gattacceca F; Evrard A; Lacarelle B; Blanchet B; Ciccolini J; Salas S
Pharmacogenomics; 2020 Feb; 21(3):173-179. PubMed ID: 31967518
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Lankheet NA; Kloth JS; Gadellaa-van Hooijdonk CG; Cirkel GA; Mathijssen RH; Lolkema MP; Schellens JH; Voest EE; Sleijfer S; de Jonge MJ; Haanen JB; Beijnen JH; Huitema AD; Steeghs N
Br J Cancer; 2014 May; 110(10):2441-9. PubMed ID: 24736581
[TBL] [Abstract][Full Text] [Related]
27. Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form.
Tiankanon K; Kerr SJ; Thongthip S; Udomkarnjananun S; Sodsai P; Vorasittha A; Panumatrassamee K; Takkavatakarn K; Tungsanga K; Eiam-Ong S; Praditpornsilpa K; Avihingsanon Y; Townamchai N
Sci Rep; 2022 Jun; 12(1):10051. PubMed ID: 35710816
[TBL] [Abstract][Full Text] [Related]
28. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Lankheet NAG; Desar IME; Mulder SF; Burger DM; Kweekel DM; van Herpen CML; van der Graaf WTA; van Erp NP
Br J Clin Pharmacol; 2017 Oct; 83(10):2195-2204. PubMed ID: 28500677
[TBL] [Abstract][Full Text] [Related]
29. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
30. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic drug monitoring of the teicoplanin trough level after the loading doses in patients receiving venoarterial extracorporeal membrane oxygenation.
Chen GJ; Lin SW; Tsai IL; Kuo CH; Wang JT; Hsieh SM
J Formos Med Assoc; 2020 Jun; 119(6):1086-1092. PubMed ID: 31672434
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors.
van Eerden RAG; Oomen-de Hoop E; Noordam A; Mathijssen RHJ; Koolen SLW
Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33557114
[TBL] [Abstract][Full Text] [Related]
33. Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer.
Fukudo M; Ishibashi K; Kitada M
Invest New Drugs; 2021 Dec; 39(6):1707-1715. PubMed ID: 34041638
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Badri PS; Parikh A; Coakley EP; Ding B; Awni WM; Dutta S; Menon RM
Ther Drug Monit; 2016 Oct; 38(5):640-5. PubMed ID: 27310199
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours - Results from daily clinical practice.
IJzerman NS; Groenland SL; Koenen AM; Kerst M; van der Graaf WTA; Rosing H; Beijnen JH; Huitema ADR; Steeghs N
Eur J Cancer; 2020 Sep; 136():140-148. PubMed ID: 32688207
[TBL] [Abstract][Full Text] [Related]
36. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
[TBL] [Abstract][Full Text] [Related]
37. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
[TBL] [Abstract][Full Text] [Related]
38. Differences in the Prediction of Area Under the Curve for a Protease Inhibitor Using Trough Versus Peak Concentration: Assessment Using Published Pharmacokinetic Data for Indinavir.
Srinivas NR
Am J Ther; 2017; 24(4):e405-e418. PubMed ID: 26291590
[TBL] [Abstract][Full Text] [Related]
39. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.
Sabanathan D; Zhang A; Fox P; Coulter S; Gebski V; Balakrishnar B; Chan M; Liddle C; Gurney H
Cancer Chemother Pharmacol; 2017 Aug; 80(2):385-393. PubMed ID: 28667354
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
